TY - JOUR
T1 - Omics Approaches to Probe Microbiota and Drug Metabolism Interactions
AU - Nichols, Robert G.
AU - Hume, Nicole E.
AU - Smith, Philip B.
AU - Peters, Jeffrey M.
AU - Patterson, Andrew D.
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/12/19
Y1 - 2016/12/19
N2 - The drug metabolism field has long recognized the beneficial and sometimes deleterious influence of microbiota in the absorption, distribution, metabolism, and excretion of drugs. Early pioneering work with the sulfanilamide precursor prontosil pointed toward the necessity not only to better understand the metabolic capabilities of the microbiota but also, importantly, to identify the specific microbiota involved in the generation and metabolism of drugs. However, technological limitations important for cataloging the microbiota community as well as for understanding and/or predicting their metabolic capabilities hindered progress. Current advances including mass spectrometry-based metabolite profiling as well as culture-independent sequence-based identification and functional analysis of microbiota have begun to shed light on microbial metabolism. In this review, case studies will be presented to highlight key aspects (e.g., microbiota identification, metabolic function and prediction, metabolite identification, and profiling) that have helped to clarify how the microbiota might impact or be impacted by drug metabolism. Lastly, a perspective of the future of this field is presented that takes into account what important knowledge is lacking and how to tackle these problems.
AB - The drug metabolism field has long recognized the beneficial and sometimes deleterious influence of microbiota in the absorption, distribution, metabolism, and excretion of drugs. Early pioneering work with the sulfanilamide precursor prontosil pointed toward the necessity not only to better understand the metabolic capabilities of the microbiota but also, importantly, to identify the specific microbiota involved in the generation and metabolism of drugs. However, technological limitations important for cataloging the microbiota community as well as for understanding and/or predicting their metabolic capabilities hindered progress. Current advances including mass spectrometry-based metabolite profiling as well as culture-independent sequence-based identification and functional analysis of microbiota have begun to shed light on microbial metabolism. In this review, case studies will be presented to highlight key aspects (e.g., microbiota identification, metabolic function and prediction, metabolite identification, and profiling) that have helped to clarify how the microbiota might impact or be impacted by drug metabolism. Lastly, a perspective of the future of this field is presented that takes into account what important knowledge is lacking and how to tackle these problems.
UR - http://www.scopus.com/inward/record.url?scp=85006800498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006800498&partnerID=8YFLogxK
U2 - 10.1021/acs.chemrestox.6b00236
DO - 10.1021/acs.chemrestox.6b00236
M3 - Review article
C2 - 27782392
AN - SCOPUS:85006800498
SN - 0893-228X
VL - 29
SP - 1987
EP - 1997
JO - Chemical research in toxicology
JF - Chemical research in toxicology
IS - 12
ER -